Global
Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Down
Syndrome-Pipeline Review, H2 2018,
provides an overview of the Down syndrome (Genetic Disorders) pipeline
landscape.
Down
syndrome is a genetic disorder that causes lifelong mental retardation,
developmental delays and other problems. Down syndrome varies in severity, so
developmental problems range from moderate to serious. Children with Down
syndrome have a distinct facial appearance. Though not all children with Down
syndrome have the same features, some of the more common features are flattened
facial features, small head, short neck, protruding tongue, upward slanting
eyes, unusual for the child's ethnic group and unusually shaped ears. Children
with Down syndrome may also have poor muscle tone, broad, short hands with a
single crease in the palm, relatively short fingers and excessive flexibility.
Global
Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Down
Syndrome-Pipeline Review, H2 2018, provides comprehensive information on the
therapeutics under development for Down Syndrome (Genetic Disorders), complete
with analysis by stage of development, drug target, mechanism of action (MoA),
route of administration (RoA) and molecule type. The guide covers the
descriptive pharmacological action of the therapeutics, its complete research
and development history and latest news and press releases.
The
Down syndrome (Genetic Disorders) pipeline guide also reviews of key players
involved in therapeutic development for Down syndrome and features dormant and
discontinued projects. The guide covers therapeutics under Development by
Companies /Universities /Institutes, the molecules developed by Companies in
Phase I, Preclinical, Discovery and Unknown stages are 2, 8, 3 and 1
respectively. Similarly, the Universities portfolio in Preclinical and
Discovery stages comprises 2 and 1 molecules, respectively.
Down
syndrome (Genetic Disorders) pipeline guide helps in identifying and tracking
emerging players in the market and their portfolios, enhances decision making
capabilities and helps to create effective counter strategies to gain
competitive advantage. The guide is built using data and information sourced
from Global Markets Direct's proprietary databases, company/university
websites, clinical trial registries, conferences, SEC filings, investor
presentations and featured press releases from company/university sites and
industry-specific third party sources. Additionally, various dynamic tracking
processes ensure that the most recent developments are captured on a real time
basis.
The
pipeline guide provides a snapshot of the global therapeutic landscape of Down syndrome
(Genetic Disorders). The pipeline guide reviews pipeline therapeutics for Down syndrome
(Genetic Disorders) by companies and universities/research institutes based on
information derived from company and industry-specific sources. The pipeline
guide covers pipeline products based on several stages of development ranging
from pre-registration till discovery and undisclosed stages. The pipeline guide
features descriptive drug profiles for the pipeline products which comprise
product description, descriptive licensing and collaboration details, R&D
brief, MoA & other developmental activities. The pipeline guide reviews key
companies involved in Down syndrome (Genetic Disorders) therapeutics and enlists
all their major and minor projects. The pipeline guide evaluates Down syndrome
(Genetic Disorders) therapeutics based on mechanism of action (MoA), drug
target, route of administration (RoA) and molecule type. The pipeline guide
encapsulates all the dormant and discontinued pipeline projects. The pipeline guide reviews latest news
related to pipeline therapeutics for Down syndrome (Genetic Disorders)
To know more click on the link below:
Contact Us:
Ken
Research
Ankur
Gupta, Head Marketing & Communications
+91
9015378249